Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids

B. Oshrine, A. Malinin, A. Pokov, A. Dragan, Daniel F Hanley, Victor L. Serebruany

Research output: Contribution to journalArticle

Abstract

Extended release dipyridamole (DIP) is widely used in clinical practice as an Aggrenox® formulation, which is proven to improve outcomes for secondary stroke prevention in patients after acute vascular events. However, presently established fluorometry techniques are not suitable for trace amount determinations, because of the variable background fluorescence. The authors sought to determine whether biological fluid pH is important for the serial measures of DIP levels in the animal experiments and in patients treated with Aggrenox® after ischemic stroke. Post-stroke patient (n = 34) and mice (n = 25) samples were tested to determine DIP levels by established techniques with FluoroMax 3 spectrofluorometer. Both the absorption and emission spectra of DIP were affected by modifications in pH. Fluorescence of DIP was found to be maximal at a wavelength of 490 nm (excitation 420 nm) and the spectral pattern was independent of pH. The intensity of fluorescence, however, was drastically lower at low pH (at pH 2.6, fluorescence was 4% of intensity at pH 9.8). Background plasma fluorescence, however, was completely unaffected by changes in pH. Using these fluorometric characteristics, a regression model that facilitates the efficient and sensitive determination of DIP concentration in biological fluids was formulated. Exploiting pH-dependent characteristics of DIP versus serum fluorescence patterns permits a convenient mathematical model to determine DIP concentration. This relatively inexpensive and time-efficient procedure can quantify drug levels in human/animal plasma/serum, thereby directly determining the level of patient adherence to the prescribed drug regimen, be it in the context of clinical trials or compliance with the animal protocol.

Original languageEnglish (US)
Pages (from-to)95-100
Number of pages6
JournalMethods and Findings in Experimental and Clinical Pharmacology
Volume27
Issue number2
DOIs
StatePublished - Mar 2005

Fingerprint

Dipyridamole
Fluorescence
Stroke
Fluorometry
Patient Compliance
Secondary Prevention
Serum
Pharmaceutical Preparations
Blood Vessels
Theoretical Models
Clinical Trials

Keywords

  • Dipyridamole
  • Fluorometry
  • pH
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids. / Oshrine, B.; Malinin, A.; Pokov, A.; Dragan, A.; Hanley, Daniel F; Serebruany, Victor L.

In: Methods and Findings in Experimental and Clinical Pharmacology, Vol. 27, No. 2, 03.2005, p. 95-100.

Research output: Contribution to journalArticle

@article{1742a719cae74770b1709b52a577b6ac,
title = "Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids",
abstract = "Extended release dipyridamole (DIP) is widely used in clinical practice as an Aggrenox{\circledR} formulation, which is proven to improve outcomes for secondary stroke prevention in patients after acute vascular events. However, presently established fluorometry techniques are not suitable for trace amount determinations, because of the variable background fluorescence. The authors sought to determine whether biological fluid pH is important for the serial measures of DIP levels in the animal experiments and in patients treated with Aggrenox{\circledR} after ischemic stroke. Post-stroke patient (n = 34) and mice (n = 25) samples were tested to determine DIP levels by established techniques with FluoroMax 3 spectrofluorometer. Both the absorption and emission spectra of DIP were affected by modifications in pH. Fluorescence of DIP was found to be maximal at a wavelength of 490 nm (excitation 420 nm) and the spectral pattern was independent of pH. The intensity of fluorescence, however, was drastically lower at low pH (at pH 2.6, fluorescence was 4{\%} of intensity at pH 9.8). Background plasma fluorescence, however, was completely unaffected by changes in pH. Using these fluorometric characteristics, a regression model that facilitates the efficient and sensitive determination of DIP concentration in biological fluids was formulated. Exploiting pH-dependent characteristics of DIP versus serum fluorescence patterns permits a convenient mathematical model to determine DIP concentration. This relatively inexpensive and time-efficient procedure can quantify drug levels in human/animal plasma/serum, thereby directly determining the level of patient adherence to the prescribed drug regimen, be it in the context of clinical trials or compliance with the animal protocol.",
keywords = "Dipyridamole, Fluorometry, pH, Pharmacokinetics",
author = "B. Oshrine and A. Malinin and A. Pokov and A. Dragan and Hanley, {Daniel F} and Serebruany, {Victor L.}",
year = "2005",
month = "3",
doi = "10.1358/mf.2005.27.2.876284",
language = "English (US)",
volume = "27",
pages = "95--100",
journal = "Methods and Findings in Experimental and Clinical Pharmacology",
issn = "0379-0355",
publisher = "Prous Science",
number = "2",

}

TY - JOUR

T1 - Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids

AU - Oshrine, B.

AU - Malinin, A.

AU - Pokov, A.

AU - Dragan, A.

AU - Hanley, Daniel F

AU - Serebruany, Victor L.

PY - 2005/3

Y1 - 2005/3

N2 - Extended release dipyridamole (DIP) is widely used in clinical practice as an Aggrenox® formulation, which is proven to improve outcomes for secondary stroke prevention in patients after acute vascular events. However, presently established fluorometry techniques are not suitable for trace amount determinations, because of the variable background fluorescence. The authors sought to determine whether biological fluid pH is important for the serial measures of DIP levels in the animal experiments and in patients treated with Aggrenox® after ischemic stroke. Post-stroke patient (n = 34) and mice (n = 25) samples were tested to determine DIP levels by established techniques with FluoroMax 3 spectrofluorometer. Both the absorption and emission spectra of DIP were affected by modifications in pH. Fluorescence of DIP was found to be maximal at a wavelength of 490 nm (excitation 420 nm) and the spectral pattern was independent of pH. The intensity of fluorescence, however, was drastically lower at low pH (at pH 2.6, fluorescence was 4% of intensity at pH 9.8). Background plasma fluorescence, however, was completely unaffected by changes in pH. Using these fluorometric characteristics, a regression model that facilitates the efficient and sensitive determination of DIP concentration in biological fluids was formulated. Exploiting pH-dependent characteristics of DIP versus serum fluorescence patterns permits a convenient mathematical model to determine DIP concentration. This relatively inexpensive and time-efficient procedure can quantify drug levels in human/animal plasma/serum, thereby directly determining the level of patient adherence to the prescribed drug regimen, be it in the context of clinical trials or compliance with the animal protocol.

AB - Extended release dipyridamole (DIP) is widely used in clinical practice as an Aggrenox® formulation, which is proven to improve outcomes for secondary stroke prevention in patients after acute vascular events. However, presently established fluorometry techniques are not suitable for trace amount determinations, because of the variable background fluorescence. The authors sought to determine whether biological fluid pH is important for the serial measures of DIP levels in the animal experiments and in patients treated with Aggrenox® after ischemic stroke. Post-stroke patient (n = 34) and mice (n = 25) samples were tested to determine DIP levels by established techniques with FluoroMax 3 spectrofluorometer. Both the absorption and emission spectra of DIP were affected by modifications in pH. Fluorescence of DIP was found to be maximal at a wavelength of 490 nm (excitation 420 nm) and the spectral pattern was independent of pH. The intensity of fluorescence, however, was drastically lower at low pH (at pH 2.6, fluorescence was 4% of intensity at pH 9.8). Background plasma fluorescence, however, was completely unaffected by changes in pH. Using these fluorometric characteristics, a regression model that facilitates the efficient and sensitive determination of DIP concentration in biological fluids was formulated. Exploiting pH-dependent characteristics of DIP versus serum fluorescence patterns permits a convenient mathematical model to determine DIP concentration. This relatively inexpensive and time-efficient procedure can quantify drug levels in human/animal plasma/serum, thereby directly determining the level of patient adherence to the prescribed drug regimen, be it in the context of clinical trials or compliance with the animal protocol.

KW - Dipyridamole

KW - Fluorometry

KW - pH

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=17044421302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044421302&partnerID=8YFLogxK

U2 - 10.1358/mf.2005.27.2.876284

DO - 10.1358/mf.2005.27.2.876284

M3 - Article

C2 - 15834462

AN - SCOPUS:17044421302

VL - 27

SP - 95

EP - 100

JO - Methods and Findings in Experimental and Clinical Pharmacology

JF - Methods and Findings in Experimental and Clinical Pharmacology

SN - 0379-0355

IS - 2

ER -